Ultimas Noticias

FDA approves Teva’s once-monthly schizophrenia treatment

Escrito por

Israeli pharmaceutical giant Teva receives FDA approval for WELTRUZA, a new long-acting injection for schizophrenia that eliminates the need for daily medication.

Israeli pharmaceutical giant Teva receives FDA approval for WELTRUZA, a new long-acting injection for schizophrenia that eliminates the need for daily medication.

Israeli pharmaceutical giant Teva receives FDA approval for WELTRUZA, a new long-acting injection for schizophrenia that eliminates the need for daily medication.

Fuente original: Leer nota completa

Acerca del Autor

Deje un comentario